Highly Potent Active Pharmaceutical Ingredients Conference USA


Boston, MA, United States

We are delighted to announce its USA Highly Potent Active Pharmaceutical Ingredients conference coming to Boston on the 21th-22th October 2019.

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers’ safety.

The event will explore how the latest technologies can benefit HPAPI with artificial intelligence and machine learning to hasten risk assessment and validation. We will also be dedication much deserved attention on emerging HPAPI therapies including bispecific antibodies, oncolytic viral complexes and hormones. Will the super-high level 5 banding for these biologics prove effective or inept? Are current containment planning and solutions truly ensuing the health of workers? Come and find the answers to these hot topics of HPAPI along with the other unique insights such as continuous HPAPI manufacturing technologies.

Attend this conference and join our networking platform for industry professionals to provide you with the expertise to overcome the challenges of the HPAPI industry.

Benefits of Attending

  • LEARN how to rationally categorise your HPAPI project into a containment banding and implement containment solutions to mitigate the occupational health risks
  • GRASP the current landscape of HPAPI ADCs and other emerging biologics-based therapies including hormones, oncolytic viral complexes, bispecific antibodies and oligonucleotide
  • DISCOVER the emerging HPAPI manufacturing technologies to reduce powder exposure with the possibility of continuous manufacturing for HPAPI
  • UNDERSTAND the steps involved to evolve a containment environment to match that of the its scale of production and value of this practice

Plus Two Interactive Half Day Post-Conference Workshops | Wednesday 23rd October 2019

Workshop A: The roadmap from assessing HPAPI hazards to containment implementation along with CDMO dynamics
Workshop Leaders: Janet Gould, Senior Managing Toxicologist, SafeBridge Consultants USA
Charlyn Reihman, Principal Occupational Health Consultant, SafeBridge Consultants USA
08.30 - 12.30

Workshop B: How to sell your containment project to management: financial justification for containment solutions
Workshop Leader: David Eherts, Vice President, Global EHS, Allergan
13.30 - 16.30

Speakers

  • Aysha Ovais, EHS Professional, Taro Pharmaceuticals
  • Dr. Anthony Haight, Senior Director, AbbVie
  • Dr. Charlyn Reihman, Principal Occupational Health Consultant, SafeBridge Consultants Ltd
  • Dr. David Eherts, Vice President Global EHS, Allergan Inc
  • Dr. Janet Gould, Senior Managing Toxicologist, SafeBridge Consultants Inc
  • Dr. Keith Jensen, Owner and Consultant, Keith Jensen Consulting
  • Dr. Patricia Weideman, President & Principal, Sakari Consultants
  • Dr. Rakesh Dixit, Vice President, R&D, Global Head, Biologics Safety Assessment, MedImmune Inc
  • Fabio Zenobi, EHS & Toxicology Director, BSP Pharmaceuticals S.p.A.
  • Joseph Grills, Former Associate Director EHS, Purdue Pharma, LP
  • Marc Abromovitz, Head of Industrial Hygiene, Novartis Pharmaceuticals Corp
  • Maurits Janssen, Senior Director, Head Of Commercial Development, Lonza Pharma & Biotech
  • Rich Arnett, Manager, Industrial Hygiene, Pharmascience Inc
  • Richard Denk, Head Containment, SKAN AG
  • Sara Martens, Associate Director, Occupational Hygiene and Containment , AbbVie

Venue

Sheraton Boston Hotel
39 Dalton Street,
Boston, MA, USA